(Q70944303)
Statements
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network (English)
G J Gorse
R B Belshe
G B Patel
1 September 1995